BRPI0919403A2 - polipeptídeos modificados de eritropoetina animal e seus usos - Google Patents

polipeptídeos modificados de eritropoetina animal e seus usos

Info

Publication number
BRPI0919403A2
BRPI0919403A2 BRPI0919403A BRPI0919403A BRPI0919403A2 BR PI0919403 A2 BRPI0919403 A2 BR PI0919403A2 BR PI0919403 A BRPI0919403 A BR PI0919403A BR PI0919403 A BRPI0919403 A BR PI0919403A BR PI0919403 A2 BRPI0919403 A2 BR PI0919403A2
Authority
BR
Brazil
Prior art keywords
modified animal
erythropoietin polypeptides
animal erythropoietin
polypeptides
modified
Prior art date
Application number
BRPI0919403A
Other languages
English (en)
Inventor
A Hays Putnam Anna-Maria
Lee Darin
Tian Feng
Song Frank
Sheffer Joseph
Atkinson Kyle
Siladi Marc
C Canning Peter
S Barnett Richard
Chu Stephaine
Original Assignee
Ambrx Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919403(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ambrx Inc, Lilly Co Eli filed Critical Ambrx Inc
Priority to BR122012024318-3A priority Critical patent/BR122012024318A2/pt
Publication of BRPI0919403A2 publication Critical patent/BRPI0919403A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0919403A 2008-09-26 2009-09-25 polipeptídeos modificados de eritropoetina animal e seus usos BRPI0919403A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122012024318-3A BR122012024318A2 (pt) 2008-09-26 2009-09-25 Polipeptídeos modificados de eritropoetina animal e seus usos

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10069208P 2008-09-26 2008-09-26
US10067908P 2008-09-26 2008-09-26
PCT/US2009/058482 WO2010036964A2 (en) 2008-09-26 2009-09-25 Modified animal erythropoietin polypeptides and their uses

Publications (1)

Publication Number Publication Date
BRPI0919403A2 true BRPI0919403A2 (pt) 2017-09-26

Family

ID=42060418

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0919403A BRPI0919403A2 (pt) 2008-09-26 2009-09-25 polipeptídeos modificados de eritropoetina animal e seus usos
BR122012024318-3A BR122012024318A2 (pt) 2008-09-26 2009-09-25 Polipeptídeos modificados de eritropoetina animal e seus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122012024318-3A BR122012024318A2 (pt) 2008-09-26 2009-09-25 Polipeptídeos modificados de eritropoetina animal e seus usos

Country Status (23)

Country Link
US (4) US8278418B2 (pt)
EP (2) EP3216800A1 (pt)
JP (1) JP5694171B2 (pt)
KR (1) KR101647164B1 (pt)
CN (2) CN107022020A (pt)
AU (1) AU2009296397B2 (pt)
BR (2) BRPI0919403A2 (pt)
CA (1) CA2737026C (pt)
CL (1) CL2011000613A1 (pt)
CO (1) CO6362016A2 (pt)
DK (1) DK2342223T3 (pt)
EA (1) EA019653B1 (pt)
ES (1) ES2631915T3 (pt)
HU (1) HUE035168T2 (pt)
IL (1) IL211600A (pt)
MX (2) MX346001B (pt)
NZ (2) NZ601659A (pt)
PE (1) PE20110832A1 (pt)
PL (1) PL2342223T3 (pt)
PT (1) PT2342223T (pt)
UA (1) UA106731C2 (pt)
WO (1) WO2010036964A2 (pt)
ZA (1) ZA201102716B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP2837392A3 (en) * 2009-09-15 2015-05-13 Kaneka Corporation Modified erythropoietin to which water-soluble long-chain molecule is added
UA107678C2 (uk) * 2009-09-23 2015-02-10 ратіофарм ГмбХ Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить його
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP3572091B1 (en) 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
WO2012097256A1 (en) * 2011-01-14 2012-07-19 University Of Tennessee Research Foundation Therapeutic compositions and methods for disorders associated with neuronal degeneration
WO2012122025A2 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
AU2012290318B2 (en) 2011-07-29 2016-09-01 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
KR102143664B1 (ko) * 2012-06-07 2020-08-11 암브룩스, 인코포레이티드 전립선 특이적 막 항원 항체 약물 접합체
KR102363779B1 (ko) 2013-01-30 2022-02-15 아벨라스 바이오사이언시즈 인코포레이티드 선택적 전달 분자 및 사용 방법
EP3194429A4 (en) * 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN108137664B (zh) * 2015-08-31 2021-11-26 宾夕法尼亚州大学信托人 用于治疗伴侣动物的aav-epo
JP6800633B2 (ja) * 2016-07-04 2020-12-16 株式会社カネカ 非ヒト動物において腎機能の低下を抑制する方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018126499A1 (zh) 2017-01-05 2018-07-12 深圳迈瑞生物医疗电子股份有限公司 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
WO2018200381A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
US11667686B2 (en) 2017-06-06 2023-06-06 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
WO2019200022A1 (en) 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
CA3121586A1 (en) * 2018-12-12 2020-06-18 Kindred Biosciences, Inc. Erythropoietin analogs for veterinary use
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
AR118536A1 (es) * 2019-04-01 2021-10-20 Genentech Inc Composiciones y métodos para estabilizar formulaciones que contienen proteína
EP3956658A4 (en) 2019-04-17 2022-12-21 DMC Global Inc. METHOD AND SYSTEM FOR IDENTIFYING A BONDING LIMIT BETWEEN A STRONG BONDING AND A WEAK BONDING IN A MULTILAYERY ARTICLE
RU2770425C2 (ru) * 2020-06-15 2022-04-18 Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Способ получения иммуноглобулина противооспенного из сыворотки крови лошадей
EP4216986A4 (en) * 2020-09-28 2024-10-16 Scout Bio, Inc. COMPOSITION AND USES THEREOF
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method

Family Cites Families (303)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
CA1341116C (en) 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US5089398A (en) 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4859600A (en) 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0164566A3 (de) 1984-05-11 1986-10-29 LGA Gastechnik GmbH Sicherheitseinrichtung für Flüssiggastanks
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
DE3587759T2 (de) 1984-05-11 1994-07-07 Chiron Corp., Emeryville, Calif. Erhöhte Hefetranskription unter Verwendung einer Hybridkonstruktion der Promotorregion.
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4612367A (en) 1985-04-08 1986-09-16 Eli Lilly And Company Process for purifying growth hormone-like materials
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US4871824A (en) 1987-03-13 1989-10-03 Minnesota Mining And Manufacturing Company Variably crosslinked polymeric supports
WO1988007082A1 (en) 1987-03-16 1988-09-22 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
DE3888561T2 (de) 1987-03-23 1994-09-01 Zymogenetics Inc Hohe Proteinsyntheserate in Hefe.
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
CA1317244C (en) 1987-07-24 1993-05-04 Ernest Seigo Kawasaki Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
WO1989001037A1 (en) 1987-07-24 1989-02-09 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
EP0318216B2 (en) 1987-11-18 2001-08-29 Chiron Corporation NANBV diagnostics
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5674706A (en) 1988-05-06 1997-10-07 Chiron Corporation High level expression of proteins in yeast
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
FR2631974B1 (fr) 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
WO1990001556A1 (en) 1988-08-05 1990-02-22 Mount Sinai School Of Medicine Of The City University Of New York In vivo infection of live insects with a recombinant baculovirus
GB8819453D0 (en) 1988-08-16 1988-09-21 Roy P Production of bluetongue virus non-structural proteins using baculovirus expression vector
NZ230425A (en) 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector
ATE112687T1 (de) 1988-09-13 1994-10-15 Chiron Corp Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
JPH04504651A (ja) 1988-11-18 1992-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自然に存在しないアミノ酸をタンパク質に部位特異的に導入する方法
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
AU5187190A (en) 1989-02-23 1990-09-26 University Of Ottawa Improved baculovirus expression system capable of producing foreign gene proteins at high levels
WO1990010277A1 (en) 1989-02-24 1990-09-07 Cell Analysis Systems, Inc. Method and apparatus for determining a proliferation index of a cell sample
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1990013540A1 (en) 1989-04-19 1990-11-15 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
CA2033070A1 (en) 1989-05-17 1990-11-18 Lois K. Miller Baculovirus expression vectors
ES2085297T3 (es) 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
DE3924746A1 (de) 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5162601A (en) 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
EP0541721A4 (en) 1990-08-02 1993-12-29 Chiron Corporation Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system
FR2665923B1 (fr) 1990-08-14 1993-01-22 Arbona Jean Unite de soins modulaire.
CA2090969C (en) 1990-09-04 2001-08-21 Russell Arthur Brierley Production of insulin-like growth factor-1 in methylotrophic yeast cells
CA2073511A1 (en) 1990-11-14 1992-05-29 Matthew R. Callstrom Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5292654A (en) 1990-12-13 1994-03-08 Whitehead Institute For Biomedical Research Mutant EPO receptor and uses therefor
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
AU1651992A (en) 1991-03-19 1992-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Expression of influenza nucleoprotein antigens in baculovirus
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6013433A (en) 1991-04-26 2000-01-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
US5506107A (en) * 1991-05-10 1996-04-09 Genentech, Inc. Selecting ligand agonists and antagonists
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
JP3210383B2 (ja) 1992-01-22 2001-09-17 株式会社東芝 ヘテロ接合バイポーラトランジスタ
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
DE69312700T2 (de) 1992-04-14 1998-02-19 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5532142A (en) 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
AU6709794A (en) * 1993-04-21 1994-11-08 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
WO1994025055A1 (en) 1993-04-29 1994-11-10 Abbott Laboratories Erythropoietin analog compositions and methods
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5491076A (en) 1993-11-01 1996-02-13 The Texas A&M University System Expression of foreign genes using a replicating polyprotein producing virus vector
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US6316254B1 (en) 1994-02-14 2001-11-13 University Of Washington Methods for stimulating erythropoiesis using hematopoietic proteins
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
JP3090586B2 (ja) 1994-03-15 2000-09-25 片倉工業株式会社 システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法
US5494892A (en) 1994-03-17 1996-02-27 International Flavors & Fragrances Inc. Methyl substituted propyl-substituted pentamethyl indane derivatives processes for producing same and perfumery uses thereof
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5686110A (en) 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5572955A (en) 1994-07-08 1996-11-12 Fambo, Inc. Animal amusement and exercising device
US6099830A (en) 1994-08-09 2000-08-08 Zymogenetics, Inc. Methods for stimulating erythropoiesis using hematopoietic proteins
US6403375B1 (en) 1994-08-24 2002-06-11 Boyce Thompson Institute For Plant Research, Inc. Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0788375A2 (en) 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996025495A1 (en) 1995-02-16 1996-08-22 Medical Research Council Sperm factor
EP0842275A1 (en) 1995-02-17 1998-05-20 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) PRODUCTION OF BIOLOGICALLY ACTIVE RECOMBINANT BOVINE FOLLICLE STIMULATING HORMONE (REC bFSH) IN THE BACULOVIRUS EXPRESSION SYSTEM
FR2732035B1 (fr) 1995-03-23 1997-05-30 Agronomique Inst Nat Rech Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
NZ308772A (en) 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
EP0886648B8 (en) * 1995-06-07 2004-03-03 Ortho Pharmaceutical Corporation Compounds and peptides that bind to the erythropoietin receptor
AU5893696A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
AU1690697A (en) 1996-01-17 1997-08-11 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin antagonists
US5861279A (en) 1996-01-17 1999-01-19 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
AU3908597A (en) 1996-08-02 1998-02-25 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US5998595A (en) 1996-11-05 1999-12-07 Wako Pure Chemical Industries, Ltd. Azidohalogenobenzyl derivatives, sugar compounds and protection of hydroxy groups
WO1998025963A1 (en) 1996-12-13 1998-06-18 Chiron Corporation Analysis and separation of platelet-derived growth factor proteins
GB9701237D0 (en) 1997-01-22 1997-03-12 Nycomed Imaging As Improvements in or relating to contrast agents
US6221608B1 (en) 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US6440526B1 (en) 1997-03-26 2002-08-27 Craig Steven John Gamble Non-slip pad
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6583267B2 (en) 1997-06-06 2003-06-24 Kyowa Hakko Kogyo Co., Ltd. Chemically modified polypeptides
US5965393A (en) 1997-07-01 1999-10-12 National Institute Of Immunology Method for enhancing foreign gene expression in baculovirus expression vector system
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
TR200000175T2 (tr) 1997-07-23 2001-01-22 Roche Diagnostics Gmbh Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
PT986644E (pt) 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
GB9715660D0 (en) 1997-07-25 1997-10-01 Zeneca Ltd Proteins
EP1003889A1 (en) 1997-08-05 2000-05-31 Chiron Corporation NOVEL $i(PICHIA PASTORIS) GENE SEQUENCES AND METHODS FOR THEIR USE
DE19735593C2 (de) 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
EP0902085B1 (en) 1997-09-01 2003-12-03 Aventis Pharma Deutschland GmbH Recombinant human erythropoietin with advantageous glycosylation profile
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
DK1015576T3 (da) 1997-09-16 2005-08-29 Egea Biosciences Llc Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer
AU752037B2 (en) 1997-09-26 2002-09-05 Uab Research Foundation Reduced antigenic cells and uses therefor
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19748489A1 (de) 1997-11-03 1999-05-06 Roche Diagnostics Gmbh Polyethylenglykol-derivatisierte Biomoleküle und deren Verwendung in heterogenen Nachweisverfahren
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
TW445295B (en) 1997-12-31 2001-07-11 Shiu Li Wei Expression vector pcDNA3.1-HC for human erythropoietin, BHK-21 host cell line transformed therewith, and production of human erythropoietin using the transformed cell
DE19803557C2 (de) 1998-01-30 1999-12-23 Koenig & Bauer Ag Antrieb für ein rotierendes Bauteil einer Druckmaschine
US6274158B1 (en) 1998-02-04 2001-08-14 Veronica L. Zaharia Czeizler Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis
WO1999040106A2 (en) 1998-02-09 1999-08-12 University Of Southern California Use of angiotensin analogues for promoting erythropoiesis
US6225060B1 (en) 1998-03-04 2001-05-01 Onyx Pharmaceuticals, Inc. Baculovirus expression system and method for high throughput expression of genetic material
ATE279430T1 (de) 1998-03-05 2004-10-15 Chiron Corp Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
KR100264953B1 (ko) 1998-04-03 2001-03-02 박현우 재조합 베큘로바이러스, 이의 제조방법 및 이를 포함하는 미생물 살충제
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
CA2330527A1 (en) 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
US6171821B1 (en) 1998-07-24 2001-01-09 Apoptogen, Inc. XIAP IRES and uses thereof
US6245528B1 (en) 1998-07-28 2001-06-12 Academia Sinica Latent baculovirus expression system
US6368825B1 (en) 1998-08-10 2002-04-09 Academia Sinica Baculovirus containing minimal CMV promoter
DE69936322T2 (de) 1998-08-28 2008-02-21 Amylin Pharmaceuticals, Inc., San Diego Polyamideketten von genauer Länge und deren Konjugate mit Proteinen
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6165283A (en) 1998-10-23 2000-12-26 Dahlin; William G. Railcar cleaning method and apparatus
WO2000026354A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
AU2346900A (en) 1998-11-30 2000-06-19 Eli Lilly And Company Erythropoietic compounds
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
JP4805432B2 (ja) 1998-12-28 2011-11-02 ランクセス・ドイチュランド・ゲーエムベーハー 木質材又は木質複合材を製造する際に使用される接着剤混入用薬剤
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
US6994986B2 (en) 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
US6342216B1 (en) 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
EP1177311B1 (en) 1999-03-17 2014-11-12 The Board Of Trustees Of The Leland Stanford Junior University In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system
US6337191B1 (en) 1999-03-22 2002-01-08 The Board Of Trustees Of The Leland Stanford Junior University Vitro protein synthesis using glycolytic intermediates as an energy source
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
ATE401908T1 (de) 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
JP2002542349A (ja) 1999-04-16 2002-12-10 ダブリューエム・マーシュ・ライス・ユニバーシティー ポリ（プロピレンフマラート）−ジアクリレートマクロマーで交差結合された生体分解性のポリ（プロピレンフマラート）ネットワーク
KR20020008186A (ko) 1999-05-11 2002-01-29 다우 케네드 제이. 에리트로포이에틴 투여의 약동학 및 약역학 모델링
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
US6485937B1 (en) 1999-10-15 2002-11-26 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
MXPA02006216A (es) 1999-12-22 2004-02-26 Nektar Therapeutics Al Corp Derivados estericamente impedidos de polimeros solubles en agua.
US6376604B2 (en) 1999-12-22 2002-04-23 Shearwater Corporation Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol)
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
GB0012997D0 (en) 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
JP2002030098A (ja) 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
JP2003104050A (ja) 2001-09-27 2003-04-09 Nippon Pop Rivets & Fasteners Ltd モール取付装置及びモールクリップ
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
ES2566761T3 (es) 2002-05-30 2016-04-15 The Scripps Research Institute Ligación de azidas y acetilenos catalizada por cobre
NZ537306A (en) 2002-07-01 2008-11-28 Kenneth S Warren Inst Inc Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
US7432092B2 (en) 2002-10-16 2008-10-07 The Scripps Research Institute Site specific incorporation of keto amino acids into proteins
CA2500653A1 (en) 2002-10-16 2004-04-29 The Scripps Research Institute Glycoprotein synthesis
EP1583816A4 (en) 2002-12-22 2007-06-13 Scripps Research Inst PROTEIN ARRAYS
US8232055B2 (en) 2002-12-23 2012-07-31 Agilent Technologies, Inc. Comparative genomic hybridization assays using immobilized oligonucleotide features and compositions for practicing the same
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
KR101171397B1 (ko) 2003-04-17 2012-08-07 더 스크립스 리서치 인스티튜트 진핵 유전자 코드의 확장
WO2005007870A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute COMPOSITIONS OF ORTHOGONAL LEUCYL-tRNA AND AMINOACYL-tRNA SYNTHETASE PAIRS AND USES THEREOF
ES2301099T3 (es) 2003-07-07 2008-06-16 The Scripps Research Institute Composiciones de parejas ortogonales lisil-arnt y aminoacil-arnt sintetasa y usos de las mismas.
EP1658366A4 (en) 2003-07-07 2006-08-09 Scripps Research Inst COMPOSITIONS OF ORTHOGONAL GLUTAMYL-TRNA AND AMINOACYL-TRNA-SYNTHETASEPAARES AND THEIR USES
ES2737837T3 (es) 2003-10-09 2020-01-16 Ambrx Inc Derivados poliméricos
CN101001866A (zh) * 2004-02-02 2007-07-18 Ambrx公司 经修饰的人类干扰素多肽和其用途
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
BRPI0513029A (pt) 2004-07-07 2008-04-22 Lundbeck & Co As H método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
EP2284191A3 (en) * 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
EP1853913A2 (en) * 2005-02-24 2007-11-14 Amgen Inc. Detection of compounds that affect therapeutic activity
EP2380435B1 (en) * 2005-08-31 2016-05-25 Kaneka Corporation Feline-derived erythropoietin and method for production thereof
KR101248252B1 (ko) * 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
PL2318029T3 (pl) 2008-07-23 2018-03-30 Elanco Us Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
US8278418B2 (en) * 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses

Also Published As

Publication number Publication date
US9644014B2 (en) 2017-05-09
IL211600A0 (en) 2011-05-31
WO2010036964A3 (en) 2010-07-15
DK2342223T3 (en) 2017-07-24
ZA201102716B (en) 2012-09-26
US20160024166A1 (en) 2016-01-28
US8278418B2 (en) 2012-10-02
CN102232085A (zh) 2011-11-02
HUE035168T2 (en) 2018-05-02
US20140011740A1 (en) 2014-01-09
EA019653B1 (ru) 2014-05-30
JP2012504136A (ja) 2012-02-16
PL2342223T3 (pl) 2017-09-29
CA2737026A1 (en) 2010-04-01
NZ601659A (en) 2014-02-28
US8569233B2 (en) 2013-10-29
US20130017995A1 (en) 2013-01-17
NZ592250A (en) 2012-11-30
IL211600A (en) 2016-02-29
EP3216800A1 (en) 2017-09-13
MX346001B (es) 2017-03-01
UA106731C2 (uk) 2014-10-10
KR20110081228A (ko) 2011-07-13
EP2342223A2 (en) 2011-07-13
CO6362016A2 (es) 2012-01-20
EP2342223A4 (en) 2013-01-23
EP2342223B1 (en) 2017-04-26
CN107022020A (zh) 2017-08-08
US20100093608A1 (en) 2010-04-15
AU2009296397A1 (en) 2010-04-01
PE20110832A1 (es) 2011-11-24
BR122012024318A2 (pt) 2019-07-30
CA2737026C (en) 2019-12-24
JP5694171B2 (ja) 2015-04-01
WO2010036964A2 (en) 2010-04-01
US9156899B2 (en) 2015-10-13
AU2009296397B2 (en) 2012-11-08
KR101647164B1 (ko) 2016-08-09
PT2342223T (pt) 2017-07-07
MX2011003272A (es) 2011-04-28
ES2631915T3 (es) 2017-09-06
CL2011000613A1 (es) 2011-08-05
EA201170491A1 (ru) 2011-10-31

Similar Documents

Publication Publication Date Title
BRPI0919403A2 (pt) polipeptídeos modificados de eritropoetina animal e seus usos
BR112012004802A2 (pt) polipeptídeos tendo atividade oxirredutase e seus usos
BRPI1016150A2 (pt) compostos heterocíclicos e seus usos.
BRPI0921862A2 (pt) inibidores de raf e seus usos
BRPI0910746A2 (pt) reticuladores e seus usos
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0912284A2 (pt) Polímeros antimicrobianos e seus usos
BRPI0810172A2 (pt) Polipeptídeos de fator vii modificado e seus usos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BR112012008074A2 (pt) derivados de piridina e pirazina como moduladores de proteína quinase
HRP20260055T1 (hr) Nehemolitički llo fuzioni proteini i njihova upotreba
BRPI1012321A2 (pt) anticorpos anti-vegf e seus usos
BR112012006501A2 (pt) polipeptídios e usos dos mesmos
DK2185693T3 (da) Differentiering af humane embryoniske stamceller
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
BR112013012132A2 (pt) composição compreendendo proteínas e oligossacarídeos hidrolisados, e seus usos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI1012340A (pt) proteínas de ligação específica e usos das mesmas
BRPI0914536A2 (pt) tiadiazoliloxifenilamidinas e o uso destas como fungicidas
BRPI0922486A2 (pt) microcápsulas e suas respectivas utilizações
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BR112012000660A2 (pt) compostos heterociclos e seus usos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AMBRX, INC. (US) , ELANCO US INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]